ANSTO nuclear technologies and the TSPO
ANSTO is a world leader in medical isotope research and application with a particularly strong history of research and development of synthetic ligands for the peripheral benzodiazepine receptor/TSPO used in preclinical and clinical research into neurodegeneration, malignant tumours and inflammatory gliosis.
Professor Richard Banati’s team has made significant contributions to the field, attracting more than a quarter of all citations, including the highest cited original scientific publication, which reported the in vivo expression of TSPO in neurodegenerative disease.
ANSTO and its partners are at the forefront of the fast growing field of TSPO research and application, and are leaders in the research and development of synthetic TSPO ligands, such as SPECT marker [123I]CLINDE and PET imaging agent [18F] PBR111, for diseases such as Alzheimer’s, Parkinson’s disease and Multiple Sclerosis.
The work on the knockout mouse model and the extensive medicinal chemistry research at ANSTO are part of a broader portfolio that ranges from structural biology using synchrotron X-ray and neutron scattering and cancer therapeutics, to environmental health studies using the largest particle accelerator infrastructure in the southern hemisphere.
The integration across several advanced biomedical technology platforms within a single organisation allows ANSTO to offer unique partnerships across disciplines and industry sectors.